PharmaCyte Biotech, Inc.

Nasdaq:PMCB

Biological Products, (No Diagnostic Substances)·LAS VEGAS, NV

CEO

Silverman Joshua

Financials

20 shown

Type	Period	Ended	Filed
10-Q	Q4 2025	10/31/25	12/18/25	→
10-Q	Q3 2025	7/31/25	9/15/25	→
10-K	FY 2025	4/30/25	8/11/25	→
10-Q	Q1 2025	1/31/25	3/17/25	→
10-Q	Q4 2024	10/31/24	12/13/24	→
10-Q	Q3 2024	7/31/24	9/17/24	→
↓

Earnings Releases (8-K)

1 shown

Filed	Period
7/11/22	Q1 FY2023	→

News (8-K)

79 shown

Filed	Type	Description
12/5/25	Delisting	Notice of Delisting or Failure to Satisfy a Continued Listing Rule	→
11/18/25	Other	8-K Filing	→
10/31/25	Exec Change	Departure or Appointment of Directors or Certain Officers	→
9/5/25	Acquisition	Entry into a Material Definitive Agreement	→
8/18/25	Agreement	Entry into a Material Definitive Agreement	→
4/24/25	Vote	Submission of Matters to a Vote of Security Holders	→
↓

Prospectuses & Registrations

29 shown

Filed	Form	Description
9/17/25	S-3	S-3	→
3/10/25	ARS	FORM ARS	→
12/4/24	S-8	REGISTRATION STATEMENT	→
3/27/24	ARS	ARS	→
9/21/23	S-3/A	S-3/A	→
9/12/23	S-3/A	AMENDMENT 2	→
↓

Filing History(455 filings)

TypeDateAccessionPeriodSize

PRE 14A

Feb 27, 2026

0001683168-26-001363PRELIMINARY PROXY STATEMENT

Mar 30, 2026

1.2 MB

SCHEDULE 13G/A

Feb 13, 2026

0001213900-26-016526

—

17.5 KB

Jan 7, 2026

0001683168-26-000148

Jan 5, 2026

15.3 KB

Jan 7, 2026

0001683168-26-000147

Jan 5, 2026

7.6 KB

10-Q

Dec 18, 2025

0001683168-25-009259FORM 10-Q FOR OCT 2025

Oct 31, 2025

5.9 MB

NT 10-Q

Dec 15, 2025

0001683168-25-009154EXTENSION

Oct 31, 2025

20.0 KB

Dec 12, 2025

0001683168-25-009116

Apr 25, 2025

8.8 KB

Dec 12, 2025

0001683168-25-009115

Apr 25, 2025

8.8 KB

Dec 12, 2025

0001683168-25-009114

Dec 12, 2025

7.1 KB

Dec 12, 2025

0001683168-25-009113

Apr 25, 2025

16.0 KB

Dec 12, 2025

0001683168-25-009112

Apr 25, 2025

9.5 KB

8-K

Dec 5, 2025

0001683168-25-008947FORM 8-K

Dec 1, 2025

189.5 KB

Nov 18, 2025

0001683168-25-008517

Sep 4, 2025

8.6 KB

SCHEDULE 13D/A

Nov 18, 2025

0001683168-25-008515

—

17.3 KB

8-K/A

Nov 18, 2025

0001683168-25-0085128-K/A

Sep 2, 2025

2.1 MB

SCHEDULE 13G/A

Nov 7, 2025

0001213900-25-107726

—

18.2 KB

8-K

Oct 31, 2025

0001683168-25-007871FORM 8-K

Oct 30, 2025

342.6 KB

DEF 14A

Oct 6, 2025

0001683168-25-007435DEFINITIVE PROXY STATEMENT

Oct 30, 2025

1.1 MB

EFFECT

Sep 26, 2025

9999999995-25-003122

—

1.9 KB

PRE 14A

Sep 24, 2025

0001683168-25-007217PRELIMINARY PROXY STATEMENT

Oct 30, 2025

305.3 KB

CORRESP

Sep 24, 2025

0001683168-25-007214

—

8.0 KB

UPLOAD

Sep 23, 2025

0000000000-25-010346

—

39.4 KB

S-3

Sep 17, 2025

0001683168-25-007041FORM S-3

—

22.4 MB

10-Q

Sep 15, 2025

0001683168-25-006991FORM 10-Q FOR JUL 2025

Jul 31, 2025

4.4 MB

8-K

Sep 5, 2025

0001683168-25-006727FORM 8-K

Sep 2, 2025

1.4 MB

25 filings shown

PharmaCyte Biotech, Inc.

Financials

Earnings Releases (8-K)

News (8-K)

Prospectuses & Registrations

Filing History(455 filings)

Proxies

Ownership

Other Filings

Filed	Form	Description
2/27/26	PRE 14A	PRELIMINARY PROXY STATEMENT	→
10/6/25	DEF 14A	DEFINITIVE PROXY STATEMENT	→
9/24/25	PRE 14A	PRELIMINARY PROXY STATEMENT	→
3/10/25	DEFA14A	FORM DEFA 14A	→
3/10/25	DEF 14A	DEFINITIVE PROXY STATEMENT	→
3/27/24	DEF 14A	DEFINITIVE PROXY STATEMENT	→
↓

Filed	Form	Description
1/7/26	4	4	→
1/7/26	4	4	→
12/12/25	4	4	→
12/12/25	4	4	→
12/12/25	4	4	→
12/12/25	4	4	→
↓

Filed	Form	Description
2/13/26	SCHEDULE 13G/A	SCHEDULE 13G/A	→
11/18/25	SCHEDULE 13D/A	SCHEDULE 13D/A	→
11/7/25	SCHEDULE 13G/A	SCHEDULE 13G/A	→
9/26/25	EFFECT	EFFECT	→
9/4/25	D	D	→
2/13/25	SCHEDULE 13G/A	SCHEDULE 13G/A	→
↓